FDA Issues Revised Draft Guidance on Charging for Investigational Drugs Under an Investigational New Drug Application

August 22, 2022

August 2022

Draft Guidance

This guidance provides information for industry, researchers, physicians, institutional review boards (IRBs), and patients about the implementation of FDA’s regulations on charging for investigational drugs under an investigational new drug application (IND) for the purpose of either clinical trials or expanded access for treatment use (21 CFR 312.8), which went into effect on October 13, 2009. Since 2009, FDA has received a number of questions concerning its implementation of the charging regulations. As a result, FDA issued the final guidance for industry Charging for Investigational Drugs Under an IND — Questions and Answers in June 2016. Since issuance of the final guidance, FDA has received questions from stakeholders through the docket and in the form of communications with review divisions. FDA is providing this revised draft guidance in a question-and-answer format, addressing the most recently asked questions.

Download the Draft Guidance Document

Draft     Level 1 Revised Guidance

Read the Federal Register Notice

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.




Agency Alerts General Regulatory

August 22, 2022

FDA Clarifies Regulations Regarding How Patients May Be Charged for Investigational Drugs

On Thursday, June 2nd the FDA issued a final guidance, entitled “Charging for Investigational Drugs Under an IND — Questions and Answers.”  The guidance provides information concerning the...

Read More
Agency Alerts General Regulatory

August 22, 2022

FDA Releases Draft Guidance Regarding the Use of Investigational Tobacco Products

Currently, there are no regulations specifically regarding investigational tobacco products. As such, at this time they are not exempt from requirements stated in the FD&C Act. Last week, FDA...

Read More
Compliance cGMP. Phase 1

August 22, 2022

Quick Guide: cGMP for Phase 1 Investigational Drugs

As Phase I clinical trials mark the first time that an investigational new drug is administered to humans, these studies are subject to appropriate current Good Manufacturing Practices (cGMP) in...

Read More